Ixekizumab Plus Tirzepatide in PsA: TOGETHER-PsA
In the 271-patient phase 3b TOGETHER-PsA trial, adults with active psoriatic arthritis and overweight or obesity were randomised to ixekizumab with or without weekly tirzepatide. The combination achieved simultaneous ACR50 and at least 10% weight loss in 31.7% versus 0.8% at week 36, and ACR50 alone in 33.5% versus 20.4%. The primary endpoint is driven by weight loss, the trial was open label, and the joint effect is the part that needs weighing: a 13-point ACR50 difference with a lower bound of 2.1.